Rapport Therapeutics, Inc. RAPP
26.03 USD +0.59 (+2.32%)
Nov 4, 2026, 11:40 AM EST
25.27 Day range 26.36
22.06 52-week range 52.93
- YTD
- -14.21%
- 1 year
- -2.33%
Financial health
Altman Z-Score
25.48 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -10.6×
FY 2022 5y median -16.3× FY 2025
P/S 0.0×
FY 2022 5y median 0.0× FY 2025
P/B 2.9×
FY 2022 5y median 2.1× FY 2025
P/FCF -16.2×
FY 2022 5y median -14.6× FY 2025
EV/EBITDA -11.2×
FY 2022 5y median -9.8× FY 2025
EV/Sales 0.0×
FY 2022 5y median 0.0× FY 2025
FCF Yield -6.2%
FY 2022 5y median -6.9% FY 2025
Profitability
Gross Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2022 5y median 0.0% FY 2025
ROE -23.0%
FY 2022 5y median -24.3% FY 2025
ROIC -25.2%
FY 2022 5y median -26.1% FY 2025
ROA -21.8%
FY 2022 5y median -23.6% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2022 FY 2025
Operating Income -50.6%
FY 2022 FY 2025
EPS (diluted) 24.3%
FY 2022 FY 2025
Free Cash Flow -31.0%
FY 2022 FY 2025
Financial Health
Current Ratio 26.2×
FY 2022 5y median 22.5× FY 2025
Quick Ratio 26.2×
FY 2022 5y median 22.5× FY 2025
Debt / Equity 0.0×
FY 2022 5y median 0.0× FY 2025
Net Debt / EBITDA 0.3×
FY 2022 5y median 1.3× FY 2025
Interest Coverage 0.0×
FY 2022 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2022 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2022 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31